5 news items
Mersana Therapeutics to Present at Upcoming Investor Conferences
MRSN
22 May 24
-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MRSN
3 May 24
-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
MRSN
2 May 24
-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MRSN
4 Apr 24
-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high
JP Morgan Upgrades Mersana Therapeutics to Neutral, Announces $5 Price Target
MRSN
19 Mar 24
JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price target.
- Prev
- 1
- Next